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Abstract  
 Background: people live at various areas of sea level may have 
different patterns of anti-hypertensive drugs. Such a relation has never been 
reported in Jordan. 
Study objectives: the current study investigated how the sea level will 
impact the prevalence of hypertension in these areas, and how will affect the 
pharmacological properties of such a population. 
Methodology: a cross-sectional study design was involved to collect data 
from study participants. A total of 1000 participants were randomly selected 
from the two study areas. 500 participants from each. Participants were 
matched for age and gender. Blood pressure were measured for all 
participants. Blood samples were withdrawn to investigate the level of 
angiotensin II. Data was collected through organizing a working excel sheet 
and was further analyzed through using SPSS version 20. Data was presented 
as means, standard deviations, frequencies and percentages. The 
relationships between variables were examined  using independent T-test. 
Significance was measured at an alpha < 0.05. 
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Study findings: the main findings of the present study were that the mean of 
SBP is significantly higher in the Dead Sea (122.42±10.53 mmHg) than the 
Sea level area (118.07±11.64 mmHg), (p=0.001). Another significant 
variable was MBP which its mean was 91.64 ±   8.90 mmHg in the Dead Sea 
and 89.84  ± 8.72 mm Hg. The difference in the mean was statistically 
significant (p=0.001). The level of angiotensin II was 8.84  ± 4.65pg/ml in 
the Dead Sea area and 11.21± 6.05pg/ml in the area of the Sea level. The 
difference in the mean of the two study areas was not statistically significant 
(p>0.05).   
Conclusions: although the level of angiotensin II was not significantly 
varied between the study areas, but its trend was to be higher in the Sea level 
area. It was surprised to have higher levels of SBP and MBP in the Dead Sea 
rather than the Seal level area. It can be implied that the therapeutic options 
of hypertensive drugs follow different patterns independent of angiotensin II 
pathways. 
 




 Hypertension is considered as a main factor associated with 
morbidity and mortality (Hasan, 2016). Epidemiological studies have 
indicated that hypertension is responsible for the majority of stroke cases and 
ischemic heart diseases. It has been estimated that the rate of chronic kidney 
disease to be approximately 22% among patients with non-diagnosed 
hypertension and 17% of those who have pre-hypertension in the USA 
(Alam et al., 2014).  
 The definition of hypertension  includes increased systolic blood 
pressure (SBP), diastolic blood pressure (DBP) or both (Chobanian et al, 
2003). 
 The treatment of hypertension is the main approach to lower blood 
pressure (BP) and it has been shown that most of the patients need more than 
one antihypertensive drug to reach  BP goals. The recommended treatments 
for hypertension include diuretics, calcium, beta-blockers, ACE-inhibitors 
and angiotensin receptor blockers (ARB) as first line treatment (Black et al., 
2001; Cushman et al., 2002; Chobanian et al, 2003; Turnbull, 2003). 
 Living at altitude areas is expected to lead to hypoxia and is 
considered as a risk factor for developing hypertension (Wolfel et al., 1985; 
Brito et al., 2007). According to the study of Luks (2007), no clear 
mechanisms explaining the increased blood pressure at high altitudes and 
further, guidelines or patient-centered strategies to control patients with 
hypertension at high altitudes are not well accepted.  In their study, Parati  et 
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al (2014) showed that treatment using the angiotensin receptor blocker 
telmisartan led to a minor decrease in the 24 h ambulatory BP at 3400 m 
altitude, but had no effect on BP at 5400 m altitude. We think that these 
findings are important and  could have impacts on the choice of 
antihypertensive treatment during travel to high altitude. 
 Study objectives: the main objectives of this study were to 
investigate how the blood pressure is affected by the Sea level and the 
possible  impacts on selection of anti-hypertensive treatments. 
 
Methodology 
 The methodology section involves the study design which was cross 
sectional to collect data from study participants within the same frame time. 
The study was conducted in two areas in Jordan, the Dead sea and the Sea 
level  The study included 1000 participants, 500 from each area. Data was 
collected through constructing a questionnaire which included the following 
variables: age, weight, height, BMI, waist circumferences, SBP, DBP, MBP, 
pulse rate, PCV, and angiotensin II. All the data were entered into SPSS 
version 20 for statistical analysis. The means and standard deviations were 
used to present data, the relationships between study variables were 
examined using independent T test, and significance was considered at alpha 
level <0.05.    
 
Results: 
General characteristics of participants  
 The data presented in table 1 and figure 1showed a general 
description of characteristics of participants and statistically compared 
between the means for each variable according to the study area. There were 
no statistically significant differences in the mean for the following 
variables: age, weight, height, BMI, and waist circumferences (p>0.05). SBP 
was significantly higher in the Dead Sea (122.42±10.53 mmHg) than the Sea 
level (118.07±11.64 mmHg) (p=0.001). No significant differences were 
observed for the mean of DBP between study areas (p>0.05). On the other 
hand, significant difference in the mean for MBP were observed so that the 
mean in the Dead Sea (91.64 ± 8.90) was higher than that in the Sea level 
(89.84  ± 8.72) (p=0.001). No significant  differences were observed for the 
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Table 1: Comparison between the Means and Standard Deviations of Blood Pressure 
and other Variables in the Dead Sea and Sea Level Areas. 
P value Sea level Dead Sea Variables 
Mean ± std Mean ± std 
NS 17.60  ± 0.51 17.60 ±  0.51 Age 
NS  67.69  ±  8.70 67.31 ± 10.77 Weight/kg 
NS 170.50±  5.85 169.29 ± 6.52 Height/cm 
NS 23.26  ±  2.57 23.45 ± 3.27 BMI 
NS 76.38  ± 6.00 76.37 ± 10.26 Waist cir./c 
0.001 118.07±11.64 122.42±10.53 SBP/mmHg 
NS 75.74  ± 8.48 76.31 ±   9.14 DBP/mmHg 
0.001 89.84  ± 8.72 91.64 ±   8.90 MBP/mmHg 
NS 79.07  ± 6.46 79.74 ±   6.17 Pulse/minute 
NS 41.50  ± 3.27 42.17 ±   3.18 PCV 
 
 
Figure 1: The means of study variables between study areas 
 
The level of Angiotensin II among study participants in study areas 
 As seen in table 2 and figure 2, the mean of angiotensin II among 
participants in the area of the Dead Sea was 8.84  ± 4.65pg/ml and this was 
lower than that of the area of the Sea level (11.21± 6.05pg/ml). The 
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Figure 2: The level of angiotensin II in study areas Discussion 
 
 The present study was conducted to examine the effect of living 
in the lowest part in the world, the Dead Sea, located in Jordan and to 
compare that with living at the Sea level area in Jordan, and to explore the 
potential of having impacts on the choice of anti-hypertensive drugs. 
 The results of our study have shown that there were no 
significant differences in the mean for personal variables including age, 
height, weight, BMI, and waist circumferences (p>0.05). It can be included 
that these variables have no impacts in hypertension variables.  
 Our findings showed that SBP and MBP were higher in the Dead 
Sea area than the Sea level area significantly (p=0.001). Actually, these 
findings are not consistent with other studies which showed increased blood 
pressure variables with altitude (Wolfel et al., 1985; Brito et al., 2007). It 
seems that the altitude difference was not enough to exert hypoxic effect 
which is reflected by having no significant difference in the mean of PCV in 
study areas. Accordingly, we may agree with the results of Luks study 
(2007) in which he pointed to poor mechanisms explaining the effects of 
altitude on hypertension.  
 The level of angiotensin II was higher in the Sea level area than 
in the Dead Sea, but not significantly (p>0.05). Other studies have confirmed 








Sea level Dead Sea
Angiotensin II 
P value Mean ± std Target Area Mean ± std Target Area 
NS 11.21± 6.05 Sea level 8.84  ±  4.65 Dead Sea  
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2014). We think that the altitude in this study was not enough to induce 
significant changes in the level of angiotensin II, and again we agree with 
Parati  et al., 2014. 
Conclusions: although the level of angiotensin II was not 
significantly varied between the study areas, but its trend was to be higher in 
the Sea level area. It was surprised to have higher levels of SBP and MBP in 
the Dead Sea rather than the Seal level area. It can be implied that the 
therapeutic options of hypertensive drugs follow different patterns 
independent of angiotensin II pathways. 
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